HOUSE_OVERSIGHT_024104.jpg

This document is a confidential financial schedule detailing the 'Healthcare Technology Portfolio' performance for two funds: Sprout Capital VII, L.P. and Sprout Growth II, L.P., as of March 31, 2014. It lists specific portfolio companies (such as WebMD, Cephalon, and Adeza Biomedical), the vintage year of investment (ranging 1994-2003), investment costs, realized values, and Internal Rates of Return (IRR). The document bears a House Oversight Bates stamp (HOUSE_OVERSIGHT_024104), indicating it was part of a congressional investigation, likely related to financial probes involving entities connected to the broader Epstein investigation.